Biocardia stock.

6 hari yang lalu ... BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of ...BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular ...SAN CARLOS, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for ...As of November 6, BioCardia’s shares were trading at $0.405. Over the past 52 weeks, the stock has experienced a significant decline of 78.11%. While BioCardia has achieved an average annual earnings growth rate of 3.7%, the Biotechs industry has seen earnings grow at a much higher rate of 21.9% annually. To stay updated on all of BioCardia ...BioCardia, Inc. (NASDAQ:NASDAQ:BCDA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ETCompany ParticipantsMiranda Peto - Investor RelationsPeter...

Mr. McClung BCDA stock SEC Form 4 insiders trading. David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.1,600 units of BCDA stock worth $4,096 on 5 November 2018.

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ... BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 2d Why Beyond Air Shares Are Trading Lower By Around 37%?

Overview News BioCardia Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-0.63 Market Cap $14.02 M 21.62 M Public Float 10.05 M Yield BCDA is...BioCardia, Inc. 0.4400. +0.0094. +2.18%. SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the ...BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.

November 15, 2023 at 8:04 AM · 3 min read. Shares of BioCardia BCDA skyrocketed 168.2% on Tuesday after management announced that the FDA approved its proposed late-stage CardiAMP Heart Failure ...

Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued.

See the latest BioCardia Inc stock price (BCDA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...16 Nov 2023 ... ... $BCDA STOCK ANALYSIS | BIOCARDIA STOCK Related topics : stock analysis stock chart stock news best stock best stocks bcda stock ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Find the latest BioCardia, Inc. (BCDAW) stock quote, history, news and other vital information to help you with your stock trading and investing.BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...Nov 16, 2023 · SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

12 Okt 2023 ... What's more, Peter Altman holds US$224k worth of shares in the company in their own name. Component, 2022, 2021, Proportion (2022). Salary, US ...BioCardia, Inc. reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Ladies and gentlemen, thank you for standing by and welcome to the ...BioCardia announces $1.3M registered direct offering priced at-the-market. The Fly • 17 days ago. Track BioCardia Inc. (BCDA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.Joseph Pantginis, an analyst from H.C. Wainwright, has initiated a new Buy rating on BioCardia ().. Joseph Pantginis’ Buy rating for BioCardia’s stock (BCDA) is based on a combination of ...Allan Tessler BCDA stock SEC Form 4 insiders trading. Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.. The largest trade Allan's ever made was buying 20,000 units of BioCardia stock on 21 …Ladies and gentlemen, thank you for standing by, and welcome to the BioCardia 2023 third-quarter conference call. (Operator Instructions) Participants of this call are advised that the audio of this conference call is being broadcasted live over the Internet and is also being recorded for playback purposes. A webcast replay of this call will be ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 17d Why Beyond Air Shares Are Trading Lower By Around 37%?

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …Oct 11, 2023 · Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...

12 Okt 2023 ... What's more, Peter Altman holds US$224k worth of shares in the company in their own name. Component, 2022, 2021, Proportion (2022). Salary, US ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...6 hari yang lalu ... GlobeNewswire. BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo...Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in fourth quarter 2024.Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.BioCardia (BCDA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright remains neutral on the stock and ...SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

Peter Altman owns over 600 units of BioCardia stock worth over $61,795 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia. Wallmine is a radically better financial terminal. ...

At the time of writing, BioCardia Inc. [BCDA] stock is trading at $0.68, down -0.92%. An important factor to consider is whether the stock is rising or falling in short-term value. The BCDA shares have gain 7.94% over the last week, with a monthly amount glided 78.71%, and seem to be holding up well over

The latest update sent BioCardia’s stock down around 20%. (Paul Campbell/Getty Images) BioCardia’s dive into its paused phase 3 heart failure trial has failed to identify reasons to be ...Nov 26, 2023 · Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ... BioCardia Inc. Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings ...BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K Nov. 16: PU BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Nov. 16: AQNov 14, 2023 · BioCardia Inc (BCDA) stock is unmoved 0% while the S&P 500 is higher by 1.44% as of 4:00 PM on Monday, Nov 13. BCDA is unmoved $0.00 from the previous closing price of $0.40 on volume of 39,170,298 shares. Over the past year the S&P 500 has gained 13.09% while BCDA has fallen -78.61%. BCDA lost -$0.63 per share the over the last 12 months. Mr. Krasno BCDA stock SEC Form 4 insiders trading. Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.. The largest trade he's ever made was buying 80,000 units of BioCardia stock on …Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...BioCardia Inc (NASDAQ: BCDA) said the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase 3 pivotal CardiAMP Cell Find the latest BioCardia, Inc. (BCDA) stock quote, history, news and other vital information to help you with your stock trading and investing.Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, …David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth 4,096$ on 5 November 2018.BioCardia Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BCDA updated stock price target summary.

Looking to buy BCDAW Stock? View today's BCDAW stock price, trade commission-free, and discuss BioCardia Inc. - Warrants (26/07/2022) stock updates with the investor community.Nov 29, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%? SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months …Instagram:https://instagram. mini dow jonesdental insurance georgiawsj cfo journaljobs that work 9 months a year Over the last 7 years, insiders at BioCardia have traded over $2,500,000 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer, and Richard M Krasno. On average, BioCardia executives and independent directors trade stock every … adobre stockjobi stock Over the last 7 years, insiders at BioCardia have traded over $2,500,000 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer, and Richard M Krasno. On average, BioCardia executives and independent directors trade stock every …BioCardia (BCDA) stock price prediction is 0.57916802735395 USD. The BioCardia stock forecast is 0.57916802735395 USD for 2024 December 01, Sunday; ... best dividend stocks of all time SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...View the latest BioCardia Inc. (BCDA) stock price, news, historical charts, analyst ratings and financial information from WSJ. The latest update sent BioCardia’s stock down around 20%. (Paul Campbell/Getty Images) BioCardia’s dive into its paused phase 3 heart failure trial has failed to identify reasons to be ...